The RAS/BRAF/MEK/ERK pathway, which operates downstream of various growth factor receptors, including EGFR, is often overexpressed and activated in CRC, particularly in cases with dysregulated MAPK pathway signaling (225). This evidence concerns the gene EGFR and colorectal carcinoma.